LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Five inspiration points in Westport’s new Freedom design showroom (Photos)
Carol Espinosa bears a striking grin as she bounds up the steps to the rejuvenation area at Freedom Interiors. Palpable excitement beams through her voice. “This is possibly my favorite part of the showroom,” she says, pointing out the lush green carpeting, comfy seating and 360-degree view of the renovated space at 4000 Washington St.…
Brazil to KC: Carol Espinosa showcases path to creativity, opportunity
She arrived in the United States with just two suitcases and her own creativity, but today Carol Espinosa fills a 7,000-square-foot Westport storefront with enough modern workplace designs to unpack for weeks, she said. “This company was built from nothing,” said Espinosa, founder of Freedom Interiors. “It started with no customers, no product offerings —…
American buying habits push Swappa to $70M in 2017 hand-me-down tech sales
Grown from a one-person, side-hustle project to a team of more than 30 people, Kansas City-based Swappa is swelling. The user-to-user marketplace for buying and selling used technology enjoyed its best year to date in 2017. The platform sold more than $70 million in hand-me-down electronics in 2017 — up about 17 percent from 2016, said…
BKS Artisan Ales takes measured approach with nano-brewery concept
It takes only about an hour for BKS Artisan Ales to sell out of its packaged bottles and cans each Saturday afternoon, Brian Rooney said. “We thought it would be great if maybe 40 people came in and maybe each of those 40 took a beer home,” said Rooney, a craft brewer who owns and…